Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [10]. - The growth was driven by both domestic recovery and overseas expansion, with significant contributions from the model animals and preclinical CRO services [10]. - The antibody development segment is progressing well, with numerous collaborations that are expected to enhance future growth potential [10]. Financial Forecasts - Revenue projections for 2025-2027 are as follows: 1.379 billion RMB (2025), 1.849 billion RMB (2026), and 2.422 billion RMB (2027), with growth rates of 40.6%, 34.1%, and 31.0% respectively [3][11]. - Net profit forecasts for the same period are: 173 million RMB (2025), 335 million RMB (2026), and 528 million RMB (2027), with growth rates of 416.4%, 93.3%, and 57.7% respectively [3][11]. - The earnings per share (EPS) are projected to be 0.39 RMB (2025), 0.75 RMB (2026), and 1.18 RMB (2027) [3][11]. Business Segments - The model animals segment saw a revenue of 274 million RMB in the first half of 2025, growing by 56.13%, while preclinical CRO services generated 155 million RMB, marking a 90.10% increase [10]. - The company launched over 400 humanized mouse models in 2025, reinforcing its leading position in the humanized animal model market [10]. - The preclinical CRO services are experiencing rapid growth, particularly in pharmacology and efficacy research, with significant increases in various service areas [10]. Collaborations and Partnerships - As of the first half of 2025, the company signed approximately 280 drug collaboration agreements with around 120 pharmaceutical companies, including 80 new agreements in the first half of 2025 [10]. - A notable collaboration involves the ADC candidate IDE034, which has entered Phase I clinical trials, with potential milestone payments of up to 406.5 million USD [10].
百奥赛图-B（02315）：海外拓展+国内回暖驱动主业增长，全年业绩表现靓丽